June 19, 2017
11 am to 12 pm EDT

Sponsored by

Webinar Description:

NGS panels are a powerful tool for parallel assessment of genomic integrity and expression across multiple targets. This facilitates biomarker discovery in early phase clinical trials and also subsequent development of CDx assays with potential utility across multiple drug targets. Almac Diagnostics will summarise the main considerations of development and analytical validation of such panels and describe our experience identifying important technical and regulatory challenges.

Learning Objectives:

• Use of NGS panels for patient selection
• Biomarker Discovery pathway in early phase trials
• A customized CDx Development approach
• Regulatory challenges and solutions

Speaker:

Dr Cheryl McFarlane

Operations Manager

Almac Diagnostics

Dr. McFarlane (PhD) has worked for over 11 years in the field of translational molecular oncology and holds the post of Operations Manager at Almac Diagnostics where she has responsibility for assay development and validation activities supporting Almac Diagnostics’ biomarker discovery, development and delivery. Prior to joining Almac in 2015, Dr McFarlane obtained a PhD from Queen’s University Belfast. She subsequently completed postdoctoral fellowships where she specialized in the identification and validation of novel therapeutic targets in the Ubiquitin Proteasome system. Cheryl is also a General Supervisor in the clinical laboratory supervising the day to day work of all CLIA certified laboratory testing.